BARK SCORPION

Symptom Recognition

Symptoms of bark scorpion stings can include pain, loss of muscle control, roving or abnormal eye movements, slurred speech, respiratory distress, hypersalivation, airway obstruction, and vomiting.¹ Symptoms are graded on a 4-point grading scale, adapted from O’Connor³:

Symptom Recognition

GRADE 1: Localized pain and/or paresthesias at the site of envenomation.

GRADE 2: Pain and/or paresthesias, remote from site of envenomation.

GRADE 3: Either cranial nerve dysfunction: tongue fasciculations, hypersalivation, slurred speech or opsoclonus. Or neuromuscular dysfunction: involuntary shaking and jerking of extremities.

GRADE 4: Both cranial nerve AND neuromuscular dysfunction.

Bark scorpion venom can affect people of all ages, but the majority of severe envenomations occur in children.³ Of the 1534 patients in the clinical trials, 78% were children.^4,*

1. Simon, RB. Bark scorpion envenomation. Nursing Critical Care. 2016;11(2):44-47.
2. Natwick ET. Scorpions. Pest Notes. 2011(74110):1-4.
3. O’Connor AD, Ruha AM. Clinical course of bark scorpion envenomation managed without antivenom. J Med Toxicol. 2012;8(3):258-262.
4. ANASCORP [centruroides (scorpion) immune F(ab’)₂ (equine)] injection Prescribing Information. Rare Disease Therapeutics, Inc.; Franklin, TN. August 2022.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
None.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Severe hypersensitivity reactions, including anaphylaxis, may occur with ANASCORP. Close patient monitoring for hypersensitivity reactions and readiness with intravenous therapy using epinephrine, corticosteroids, and diphenhydramine hydrochloride is recommended during the infusion of ANASCORP. If an anaphylactic reaction occurs during the infusion, terminate administration at once and administer appropriate emergency medical care.

Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. Patients who have had previous therapy with ANASCORP or another equine antivenom/antitoxin may have become sensitized to equine protein and be at risk for a severe hypersensitivity reaction.

Delayed Allergic Reactions (Serum Sickness)
Monitor patients with follow-up visit(s) for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia), and treat appropriately if necessary. Eight out of 1,534 (0.5%) patients in the clinical trials exhibited symptoms suggestive of serum sickness.

Transmissible Infectious Agents
ANASCORP is made from equine (horse) plasma, it may therefore carry a risk of transmitting infectious agents, e.g., viruses.

Reaction to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANASCORP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.

ADVERSE REACTIONS
The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus.

Please see complete Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Rare Disease Therapeutics, Inc., at 1-844-472-7389 or by email at safety@raretx.com, or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.